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Abstract
Fanconi anemia (FA) is caused by mutations of DNA repair genes. The risk of oral squamous cell 
carcinoma (OSCC) among FA patients is 800-folds higher than in the general population. Early 
detection of OSCC, preferably at it precursor stage is critical in FA patients to improve their 
survival. In an ongoing clinical trial, we are evaluating the effectiveness of the programmable bio-
nano-chip (p-BNC)-based oral cytology test in diagnosing oral potentially malignant disorders 
(OPMD) in non-FA patients. We used this test to compare the cytomorphometric and molecular 
biomarkers in OSCC cell lines derived from FA patients and non-FA patients and brush biopsy 
samples of a FA patient’s OPMD and normal mucosa of healthy volunteers. Our data showed that 
expression patterns of molecular biomarkers were not notably different between sporadic and FA 
OSCC cell lines. The p-BNC assay revealed significant differences in cytometric parameters and 
biomarker MCM2 expression between cytobrush samples of the FA patient and cytobrush samples 
of normal oral mucosa obtained from healthy volunteers. Microscopic examination of the FA 
patient’s OPMD confirmed the presence of dysplasia. Our pilot data suggests that p-BNC brush 
biopsy test recognizes dysplastic oral epithelial cells in a brush biopsy sample of a FA patient.
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Introduction
Oral and oropharyngeal squamous cell carcinomas (OSCC) represent the sixth most 
commonly diagnosed cancer, with an estimated 500,000 new cases diagnosed annually 
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worldwide and accounting for approximately 3% of new cancer cases in the United States 
(Ferlay et al., 2010). Despite advances in diagnostic and therapeutic modalities, five-year 
relative survival rate has remained low (60%) for the past three decades, possibly secondary 
to presentation of patients at late stages of disease (Vigneswaran & Williams, 2014). Both 
incidence and mortality rates of OSCC vary considerably depending on the anatomic 
location of the tumor (Vigneswaran & Williams, 2014). The tongue is the most common site 
for OSCC among both European and US populations and tongue cancers carry a less 
favorable prognosis compared to other oral anatomic sub-sites (Chen & Myers, 2001, 
Warnakulasuriya, 2009, Vigneswaran & Williams, 2014). The locoregional relapse rates 
remain high for tongue SCC and as a result the prognosis of a patient diagnosed with tongue 
cancer is poor, particularly when the disease is diagnosed in its advanced stages. Hence, 
early detection of tongue SCC is critical to improve survival rates. Furthermore, patients 
treated for OSCC are at risk of developing secondary primary tumors at a rate of 3.7% per 
year, accounting for one-fourth of all OSCC-related deaths, because of “field cancerization” 
(Day & Blot, 1992). Therefore, close surveillance of patients who were successfully treated 
for oral cancer is critical for early detection of recurrences and/or second primaries.
The majority of patients diagnosed with OSCC reside in low- and middle-income countries 
(Warnakulasuriya, 2009). In the Indian subcontinent and neighboring countries, OSCC ranks 
first in prevalence among all cancers in males and third in females (Warnakulasuriya, 2009). 
Owing to their limited health care resources, developing countries cannot afford the model 
used for screening and diagnosis of OSCC that is used in developed countries. Therefore, 
OSCC patients from these countries are diagnosed at a late stage when treatment is more 
expensive and less successful than when patients are diagnosed at earlier stages. Hence, 
development of a simple, reliable and non-invasive test for diagnosis of OSCC at an early 
stage, ideally during its precursor stage will certainly improve the chances for curative 
treatment.
Similar to common solid malignancies, OSCC development is a multistep process often 
preceded by precursors, which are commonly known as oral potentially malignant disorders 
(OPMD). These include premalignant lesions and conditions that have an increased risk for 
malignant transformation (Warnakulasuriya et al., 2007). Premalignant lesions are defined 
as morphologically altered oral mucosae in which OSCC is more likely to develop (i.e. 
Leukoplakia and Erythroplakia) (Warnakulasuriya et al., 2007, van der Eb et al., 1993). 
Premalignant conditions are defined as intraoral conditions that are associated with a 
substantially increased risk for OSCC and can include oral lichen planus, oral graft versus 
host diseases (GVHD), and oral submucous fibrosis (Warnakulasuriya et al., 2007).
Individuals, who smoke cigarettes, use smokeless tobacco and/or areca nut, consume 
excessive alcohol and have persistent oral infections with high-risk oncogenic human 
papilloma virus (HPV) are at a higher risk for developing sporadic OSCC (Vigneswaran & 
Williams, 2014). In addition, patients with Fanconi anemia (FA; MIM 227650) exhibit 
inherited risk for developing OSCC even in the absence of the above mentioned risk factors. 
FA is a chromosomal instability disorder inherited as an autosomal- or X-chromosomal 
recessive trait. It is caused by germline mutations in one of 15 FA genes involved in the 
DNA repair pathway, resulting in increased risks for bone marrow failure, leukemia and 
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solid malignancies (Levitus et al., 2006). The risk of OSCC among FA patients is 800-times 
higher than in the general population, occurring at younger ages (median age: 27-years) 
(Kutler et al., 2003a, Masserot et al., 2008). Further, OSCC in FA patients is highly 
aggressive with poor prognosis (Bachoura & Vigneswaran, 2014). Early intervention and 
aggressive surgical management are needed because radiation and chemotherapy are 
contraindicated due to significant adverse risks in these patients (Scheckenbach et al., 2012). 
Moreover, FA-OSCC patients have a higher risk for developing multiple primary tumors 
than the general population due to the presence of multifocal pre-malignant disease. Hence, 
semi-annual oral cancer screening is recommended for FA patients beginning at a young age 
(Singh, 2008).
Visual and tactile examination of the oral cavity by a trained oral health care provider under 
white light remains to be the gold standard for oral cancer screening (Lingen et al., 2008). 
Unlike cervical cancer were Papanicolaou (PAP) smears are instrumental in cancer 
screening, cytology for oral cancer screening has not been proven effective (Dolens Eda et 
al., 2013, Folsom et al., 1972). Histopathologic examination of the tissue biopsy is the gold 
standard for diagnosing OED or invasive carcinoma (Lingen et al., 2008). Although tissue 
biopsy is ideal for diagnosing and monitoring the progression of OPMD towards OSCC, 
frequent re-biopsy of OPMD in FA patients is impractical, expensive, discomforting and 
associated with significant complications. Moreover, scalpel biopsy has significant sampling 
limitation in FA patients because of diffuse and multifocal involvement of OPMD. Hence, 
regular and meticulous clinical examination by an expert clinician remains the only option 
currently available for detection and monitoring of OPMD in FA patients. However, such 
expert clinical services are not usually available in the community dental and medical clinics 
where most FA patients seek care. Hence, there is a desperate need for an objective non-
invasive test for surveillance and monitoring for OPMD in FA patients that can be 
performed in a community dentist’s or physician’s office.
In an ongoing clinical trial, we are evaluating the effectiveness of a programmable 
bionanochip (p-BNC)-based oral cytology test in diagnosing OED and OSCC compared to 
the standard tissue biopsy diagnosis. The p-BNC assay integrates multiple laboratory 
processes within a microfluidic platform in three primary steps consisting of: (i) cell 
separation/capture on the membrane filter, (ii) biomarker immunolabeling and cytochemical 
staining, and (iii) computer assisted image and data analysis. The p-BNC assay is used to 
measure a combination of cytomorphometric features and biomarker expression levels in 
cell samples collected using a transepithelial brush biopsy to discriminate benign, dysplastic 
and malignant oral epithelial cells. Six antibodies against biomarkers are used in the p-BNC 
assay which label either the cell surface (EGFR: Epidermal Growth Factor Receptor, 
CD147/EMMPRIN: Extracellular Matrix MetalloPRoteinase Inducer and αvβ6 integrin) or 
the nucleus (MCM2: MiniChromosome Maintenance protein 2, geminin and Ki67). These 
biomarkers were chosen based on previous studies reporting their utility in distinguishing 
benign, dysplastic and malignant oral epithelial cells (Torres-Rendon et al., 2009, 
Vigneswaran et al., 2006, Weigum et al., 2010). In this report, we present the data from a 
pilot study that we conducted to evaluate the value of the p-BNC based oral cytology test as 
an adjunct to the standard oral cancer screening for the diagnosis of OPMD in FA.
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Materials and methods
Cell lines
The human FA-OSCC cell lines VU-1365 and VU-1131were obtained from Dr. Ruud H. 
Brakenhoff (Vrije University Medical Center, The Netherlands) and OHSU-974 was a gift 
from Dr. Laura Hayes (Oregon Health and Science University, Oregon, USA)). The human 
sporadic OSCC cell lines UMSCC-22A and UMSCC-101A were obtained from Dr. Thomas 
E. Carey, University of Michigan, and MDA-686Tu was a gift from Dr. Peter G. Sacks 
(NYU College of Dentistry). Molecular phenotypes of these cell lines have been defined in 
published reports and are shown in Table 1 (Brenner et al., 2010, van Zeeburg et al., 2005). 
These cell lines were grown in adherent conditions using the recommended culture medium 
and used for p-BNC assay as described previously.
Patient information
This study was conducted as part of a large non-interventional clinical trial which evaluated 
the usefulness of a p-BNC brush test in the diagnosis and management of patients presenting 
with OPMD. This study was reviewed, approved and monitored by the Institutional Review 
Boards of the University of Texas Health Science Center at Houston and Rice University, 
Houston, Texas. The FA patients for this study were recruited at the Meeting for Adults with 
FA, held in Baltimore, Maryland in March 2014. Twenty-six patients attending this camp 
voluntarily consented to participate in an oral cancer screening and to undergo a brush 
biopsy if an OPMD was detected during screening. After informed and written consent, 
participants were subjected to a conventional oral examination (COE) under white light, as 
well as a tissue autofluorescence examination using VELscope. During screening, a 34-year 
old male FA patient presented with a large white plaque (leukoplakia) in the right lateral and 
ventral surfaces of the tongue. Brush biopsy sample was taken from this lesion using the 
Rovers® Orcellex® oral cytology brush (Rovers Medical Devices B.V., Oss, The 
Netherlands). For healthy volunteers (n=10), a brush biopsy was taken from the normal 
appearing mucosa on the lateral surface of the tongue. The brush was applied directly to the 
lesion and normal mucosa using mild pressure and rotated 360° for 15 times in the same 
direction to collect the cellular samples. Cells were recovered by vortexing the brush tip in 
brush biopsy transport/storage media (CytoLyt® or MEM culture media). The cells stored in 
the MEM culture media were washed, re-suspended in a cryo-preservative (FBS with 10% 
DMSO) and stored at −80°C until processing for p-BNC assay. Cells stored in CytoLyt® 
media did not require further processing.
p-BNC assay sample processing
Cultured OSCC cells and cytobrush cells samples collected from the FA patient and normal 
tongue mucosa of healthy volunteers (n=10) were processed for p-BNC assay. Prior to 
sample processing on the p-BNC platform, cell samples were fixed in 0.5% formaldehyde 
for one hour, washed twice in PBS, and resuspended in 150 μL of PBS with 0.1% BSA. 
After priming the fluidic tubing and p-BNC device with PBS, the cell suspension was loaded 
into an injection port and delivered over the membrane for two minutes at a flow rate of 
1.5mL/min followed by a PBS wash step for 2.5 minutes at 1mL/min. Primary antibody 
solutions against EGFR, CD147, αvβ6, MCM2, geminin and Ki67 in PBSAT (0.1% PBS + 
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0.1% BSA + 0.1%Tween-20) were then delivered over the captured cells for 2.5 min at a 
flow rate of 250 μL/min, followed by a second PBS wash step. The final staining cocktail 
consisting of AlexaFluor®488-labelled secondary antibodies (green), a nuclear stain 4′,6-
diamidino-2-phenylindole (DAPI; blue) and a cytoplasmic stain phalloidin-AlexaFluor®647 
(red) in PBSAT was delivered over the captured cells in the same fashion as the primary 
antibody. After a final PBS wash step, a custom imaging sequence automatically recorded 
25 fields of view at three different z-slices for a total imaging area of 20mm2.
Image analysis
Enhanced depth-of-field was achieved by utilizing a custom focusing algorithm that 
combined the three different z-slices at each field of view. Individual cell outlines were 
identified by applying adaptive thresholds to DAPI and Phalloidin channels for each image 
(Cell Profiler, www.cellprofiler.com) (Carpenter et al., 2006) and used to create regions of 
interest (ROIs) specific to each cell. These ROIs were then analyzed through automated 
custom macros (ImageJ, Matlab) to obtain cytomorphometric and molecular data at a single-
cell level.
Data analysis
The normal control group consisted of 10 lesion-free healthy volunteers who provided brush 
biopsy samples of their tongue and buccal mucosa. To maintain site-specific consistency, 
only brush biopsies of the tongue from the same clinical site were included in the analysis. 
Lone nuclei and cellular debris were identified and flagged through the use of several filters 
based on criteria for different morphometric parameters. These objects were removed from 
analysis in order to concentrate on whole, intact cells. After data filtering, there were a total 
of 104 individual cells present in the Fanconi-Anemia subject and 18,140 individual cells 
combined between the 10 healthy volunteers in the database. For each morphometric and 
molecular parameter, a one-way analysis of variance (ANOVA) test (significance level of α 
= 0.05) was performed to identify significant differences between the two populations.
Results
p-BNC assay of FA and sporadic OSCC cell lines
During this automated assay procedure, a cell suspension is delivered to the disposable bio-
nanochip (BNC) using a pressure-driven flow, whereupon cells larger than the membrane 
pore size are retained on the membrane surface (Figure 1). The captured cells are stained 
with fluorescent dyes and primary and secondary immuno-reagents. Cellular cytoplasm 
counterstained with phalloidin/AlexaFluor®-647 appears red and its nucleus counter stained 
with DAPI appears blue (Figure 2). The expression levels and patterns of molecular 
biomarkers are detected by green fluorescence (AlexaFluor®488). Fluorescence microscopy 
is performed in an X, Y, Z scan of the membrane surface and is followed by automated 
image analysis for quantitative intensity standardization and cell/nuclear contouring from 
the red/blue/green channels (Figures 1 & 2). Sporadic (UM-SCC-22A and MDA-686-Tu) 
and FA-OSCC cell lines (VU-1365, VU-1131 and OHSU-974) did not show any significant 
differences in the expression patterns of these biomarkers (Figure 3). Except for geminin, 
expression all five biomarkers are detected in both sporadic and FA OSCC cells (Figure 3); 
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however, the expression patterns of these biomarkers are heterogenous within each cell line. 
Nuclear abnormalities such as bi-nucleated tumor cells and tumor cells with micronucleus 
are frequently noted in FA-OSCC cells compared with sporadic OSCC cells (Figure 4).
p-BNC assay of brush biopsy samples
The p-BNC data of the brush biopsy sample obtained from the FA patient’s OPMD was 
compared with brush biopsies of the ten healthy volunteers. We limited our biomarker 
selection to MCM2, which allows a better discrimination between benign, dysplastic and 
malignant oral epithelial cells, based on unpublished preliminary studies. Results from the 
ANOVA tests for each parameter are summarized in Table 1. Overall, it was found that the 
brushed cells from the FA patient’s tongue lesion expressed a significantly higher level of 
the nuclear biomarker MCM2 than the healthy controls and also exhibited distinct 
morphological characteristics such as increased cell area, increased nuclear area, increased 
cell circularity, and increased nuclear-to-cytoplasm ratio. In this study, nuclear-to-cytoplasm 
ratio was defined as the total nuclear area divided by the whole cell area; and circularity was 
defined as 4pi (area/perimeter^2), resulting in a value between 0 and 1 where a value of 1 
indicates a perfect circle. Common cell morphologies are presented for both brushed cells 
from the tongues of normal volunteers (Figure 5A) and the OPMD of the FA patient (Figure 
5B). In addition to the fewer number of cells observed across different imaging fields for the 
FA subject, the cells also exhibit a higher degree of circularity as well as enlarged nuclei. 
While no significant difference was seen in cell area by analyzing the combined cell 
populations, small sub-populations of cells with unique morphologic features can be 
extracted from density plots, such as seen in Figure 6.
Excisional biopsy of the erythroleukoplakia in the FA patient
The FA patient presented with a diffuse area of mixed red and white plaque involving the 
right lateral and ventral surface of the tongue which measured approximately 2.8 × 2.1 cm 
(Figure 7). Tissue autofluorescence examination with VELscope showed loss of 
fluorescence of this OPMD. The patient was advised to consult his head and neck surgeon 
for further diagnostic evaluation and treatment. Subsequently, this lesion was excised and 
submitted for histopathologic examination. Microscopic examination of the excisional 
biopsy revealed moderate epithelial dysplasia and no evidence of an invasive cancer (Figure 
8). The surgical margins were free of dysplasia.
Discussion
In this case report, we present the pilot data to demonstrate the feasibility of a programmable 
bio-nanochip (p-BNC) brush biopsy test as a non-invasive method for early detection of 
OSCC at its precursor stage of OED. This exploratory study is aimed to evaluate the 
effectiveness of using a p-BNC brush biopsy test for surveillance of OSCC and its 
precursors in the high risk FA patient population.
Fanconi anemia is an inherited cancer syndrome with an increased risk for head and neck 
squamous cell carcinomas (HNSCC) (Kutler et al., 2003a, Masserot et al., 2008, 
Scheckenbach et al., 2012). It is a rare autosomal recessive DNA disorder caused by 
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mutations in at least one of the 15 genes in the FA pathway which regulates cell cycle check 
point and DNA repair (Levitus et al., 2006). Clinically, FA is characterized by various 
congenital malformations, increased risk for malignancies and progressive bone marrow 
failure (Kutler et al., 2003b). It is estimated that malignancies are 10,000–15,000-fold higher 
in FA patients than in the general population (Deeg et al., 1996). Hematopoietic stem cell 
transplantation (HSCT), which greatly extends the life-expectancy in FA patients, appears to 
increase the risk of malignancies in these patients. The cumulative incidence of head and 
neck cancers in bone marrow transplanted FA patients is estimated to be 100% by 45-years 
of age, whereas the risks in FA patients who have not had HSCT is 50%. (Rosenberg et al., 
2005). Development of chronic oral graft-versus-host disease (GVHD) in FA patients who 
have undergone HSCT increases their risk for OSCC. Furthermore, prolonged 
immunosuppressive treatment for chronic oral GVHD also increases the risk for OSCC in 
these patients. More than two thirds of the HNSCC in FA patients are OSCC, and the tongue 
is the most common subsite for OSCC (Kutler et al., 2003a, Masserot et al., 2008, 
Scheckenbach et al., 2012). The condition of OSCC in FA patients occur at a younger age 
than the general population (median age: 27-years) and have a worse prognosis (Birkeland et 
al., 2011, Scheckenbach et al., 2012, Bachoura & Vigneswaran, 2014). One of the most 
significant clinical challenges in the management of FA patients with OSCC is that most of 
these patients present with a locally advanced stage of this disease (Singh, 2008). 
Management of locally advanced OSCC in FA patients is more difficult than in the general 
population because chemo- and radiation therapies are not recommended for managing solid 
cancers in FA patients. These patients have increased sensitivity to DNA-cross linkers and 
susceptibility to radiation-related toxicity in non-cancerous tissues due to inherent defects in 
their DNA repair pathways. Currently, surgical resection is the only treatment option 
available for FA patients with OSCC. Surgery is effective in FA tongue cancer only if it is 
detected at an early stage, preferably during the precancer stage (Singh, 2008). OSCC in FA 
patients frequently occurs as a multifocal disease and is often preceded by premalignant 
lesions manifesting as leukoplakias (Singh, 2008). Therefore, it is strongly recommended 
that FA patients undergo semi-annual oral cancer screenings by conventional oral 
examination, beginning by the age of 10–12 years (Singh, 2008). High-risk FA patients with 
oral leukoplakias or chronic GHVD and those who have a history of total-body radiation are 
recommended to undergo oral cancer screening every three months. Distinguishing OPMD 
from a benign keratosis (i.e. frictional keratosis) and inflammatory oral mucosal lesion by 
conventional oral examination can be challenging and is dependent upon the skill of the 
examiner (Lingen et al., 2008). Even experienced practitioners will have difficulty in 
recognizing subtle clinical findings indicative of malignancy in FA patients because of the 
high prevalence of chronic mucositis related to GVHD, xerostomia and opportunistic 
candidiasis. To date, the diagnosis and management of OPMD in the general population is 
based on visual inspection by COE with scalpel biopsy of lesions deemed clinically 
suspicious. Although COE has been shown to have a high discriminatory ability in 
distinguishing normal and abnormal oral mucosal patterns, it has poor sensitivity and 
specificity in discriminating oral premalignant and malignant lesions from benign reactive 
and inflammatory oral mucosal lesions (Lingen et al., 2008, Shin et al., 2010). Poor 
specificity of oral cancer screening by COE frequently leads to unnecessary biopsies. As a 
surgical procedure, a biopsy is invasive and the selection of a representative biopsy site is 
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always problematic in OPMD with diffuse or multifocal involvement, as is the case of 
OPMDs in FA patients. Usually, diagnosis of OPMD in FA patients requires referral to a 
specialist and surgical biopsy of suspicious lesions is often delayed due to various reasons. 
Many clinicians in the community are reluctant to perform invasive biopsies delaying the 
diagnosis. Therefore, an effective non-invasive surveillance method that can reliably aid the 
clinician in identifying OPMDs most likely to progress to OSCC in FA patients is 
desperately needed. Development of a simple and non-invasive diagnostic test, which can be 
administrated in resource-limited settings, will make it possible to identify OSCC in FA 
patients in earlier stages, thus reducing the number of unnecessary biopsies.
There are a number of commercially available adjuncts for COE that have been developed 
and marketed to oral health providers for the detection and diagnosis of OPMD. These 
adjunctive techniques include imaging of oral mucosa using a hand held tissue reflectance or 
autofluorescence based devices and oral exfoliative cytology. Efficacy and limitations of 
these tests in detecting and diagnosing OPMD are discussed elsewhere (Lingen et al., 2008, 
Shin et al., 2010).
Oral exfoliative cytology is a diagnostic test which consists of microscopic examination of 
epithelial cell samples scraped from the surface of the mucosal lesions. Contrasting the 
cervical Papanicolaou (PAP) smear, a well-established test for screening cervical cancer, 
oral exfoliative cytology is not advocated for screening of OSCC and its precursors. Most 
clinicians feel that the sensitivity of oral exfoliative cytology, with a reported false negative 
rate as high as 31%, is not sufficient to warrant its widespread use in the diagnostic 
evaluations of OPMD(Dolens Eda et al., 2013, Folsom et al., 1972). This is due to the fact 
that exfoliative cells obtained by scraping the lesional surface are often devoid of basal and 
parabasal cells and therefore is not representative of the whole thickness of the epithelium. 
A renewed interest in oral cytology started after the introduction of brush cytology test 
known as OralCDx (OralCDx Laboratories Inc., Suffern, NY) (Sciubba, 1999). This 
technology utilizes a small wire brush, similar to the one used in the current study, to obtain 
cells representing the whole thickness of the epithelium (transepithelial). This brush biopsy 
test reports the results as “negative/benign” or “positive” or “atypical” and the samples 
yielding positive or atypical test results will need scalpel biopsy for a definitive diagnosis. 
The major limitation of the brush cytology test is its poor positive predictive values, as low 
as 38%, which leads to many unnecessary biopsies (Lingen et al., 2008). To improve the 
positive predictive value, the p-BNC brush biopsy test uses quantitative measurements to 
characterize multiple cytometric and molecular biomarkers within the same cell samples. In 
contrast to the p-BNC brush test, the conventional brush cytopathologic diagnosis relies on 
the qualitative assessment of the cellular and nuclear morphologies and is associated with a 
high degree of inter-and intraobserver disagreement, depending on the experience of the 
pathologist.
In an ongoing non-interventional clinical trial, we used the p-BNC assay to measure the 
cytometric and molecular biomarkers on brush biopsy samples of 775 non-FA patients with 
OPMD who needed scalpel biopsy for the diagnosis. The p-BNC brush biopsy data base, 
consisting of key cytometric and molecular biomarker signatures of these patients’ samples, 
is being used to develop a diagnostic model for classifying OPMDs into benign, dysplastic 
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and malignant. The data from this clinical trial will be published elsewhere. The p-BNC 
assay provides an objective and reproducible quantitative data, independent of pathologist’s 
fatigue, experience, and inter- and intraobserver variability which are the critical drawbacks 
of conventional cytopathology.
In our preliminary studies, we used the p-BNC assay to examine the cytometric and 
molecular biomarker signatures of established cell lines derived from sporadic and FA 
OSCC. Our data showed that expression patterns of molecular biomarkers CD147, EGFR, 
Ki67, McM2, Geminin, αvβ6 integrin were not notably different between sporadic and FA 
OSCC cell lines. These findings are in line with the previously published reports showing 
that molecular phenotypes of FA and sporadic oral cancer cells are similar except for their 
sensitivity to cisplatin (van Zeeburg et al., 2005).
Next we tested whether the p-BNC brush test is capable of detecting dysplastic oral 
epithelial cells in a brush biopsy from a FA patient who presented with clinically high-risk 
OPMD. The data from the assay revealed significant differences in cytometric parameters 
(nuclear area, cell circularity) and biomarker MCM2 expression between cytobrush samples 
of the FA patient and site matched healthy volunteers (Table 1). Based on the clinical and p-
BNC assay findings, the patient was advised to consult his head and neck surgeon for further 
evaluation. Subsequently, the lesion was excised and the presence of oral epithelial 
dysplasia in the surgical specimen was confirmed by histopathologic examination. In this 
study, we compared the brush sample of the lesion with brush biopsies from the normal 
mucosae of healthy volunteers, because of the lack of clinically normal appearing mucosa 
on the contralateral side of the patient’s tongue. Obtaining brush biopsy samples from 
clinically normal oral mucosa for comparison can be difficult in FA patients because of 
increased prevalence of chronic oral mucositis and multifocal nature of precancers in these 
patients. The need for brush samples of normal mucosa will not be necessary after the 
diagnostic model to interpret the p-BNC data is developed. FA OSCC cell lines were 
associated with elevated number of bi-nucleated tumor cells and tumor cells with 
micronuclei reflecting their DNA repair defects. However, similar cells were not detected in 
the patient’s brush biopsy sample and therefore more FA patients’ brush biopsy samples 
need to be tested before determining their diagnostic utility and biologic significance of 
nuclear aberrations and micronuclei in OPMD’s of FA patients.
In conclusion, this non-invasive p-BNC brush biopsy test distinguishes dysplastic oral 
epithelial cells in a brush biopsy sample of a FA patient’s leukoplakia from normal oral 
brush biopsy samples of healthy volunteers. We want to acknowledge that the findings of 
this study are limited to a single FA patient and cannot be generalized to all FA patients with 
OPMD. Additional studies involving more FA patients with OPMD are needed to 
substantiate these findings. Considering FA is a rare disorder, it will take a longer time to 
recruit sufficient sample size to determine the sensitivity and specificity of the p-BNC based 
cytology compared to scalpel biopsy in diagnosing oral epithelial dysplasia and invasive 
carcinoma.
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Figure 1. 
Programmable Bio-Nano-Chip Assay (p-BNC) Instrumentation and Work Flow. 
Fluorescence-microscopy images of cells stained with a cocktail of fluorescent dyes and 
antibody- based reagents such that the cytoplasm appears red (Phalloidin-AlexaFluor-647), 
the nucleus blue (4′-6-diamidino-2-phenylindole: DAPI), and biomarker is green 
(AlexaFluor-488). PMMA: Poly (methyl methacrylate).
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Figure 2. 
Automated single cell measurement capability of p-BNC assay. In the raw image (A), 
individual cell outlines were identified by applying adaptive thresholds to DAPI and 
Phalloidin channels for each image (B) and used to create regions of interest (ROIs) specific 
to each cell (C &D). These ROIs were then analyzed through automated custom macros 
(ImageJ, Matlab) to obtain cytomorphometric and molecular data at a single-cell level. 
Measurements up to 20 parameters (i.e. area, mean value, standard deviation, modal value, 
centroid, center of mass, perimeter, bounding rectangle, fit ellipse, circularity, Feret’s 
diameter, median, integrated density) are made for each color (Red, Green, Blue) separately 
for the cytoplasm and the nucleus.
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Figure 3. 
Biomarker expression patterns in sporadic (686TU & 22A) and FA (VU1365, VU1131 & 
OHSU974) OSCC cell lines. Expression levels of these biomarkers in tumor cells are 
heterogenous among different cell lines as well as within the same cell line. However, there 
were no notable differences in the expression patterns of these biomarkers between FA and 
sporadic OSCC cell lines.
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Figure 4. 
Representative images illustrate the increased occurrence of binucleated and micronucleus 
in FA OSCC cell lines.
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Figure 5. 
Representative images of brush biopsy samples processed by p-BNC device. Each image is 
a false-color merged monochrome fluorescent image where the phalloidin dye is seen in red 
to discern the cytoplasm and DAPI is seen in blue to identify the nuclei. Row A includes 
randomly selected cells from the normal volunteer group and Row B includes randomly 
identified cells from the FA patient. The scale is the same between each image and the scale 
bar represents 200μm.
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Figure 6. 
Density scatter plots depicting the log mean nuclear MCM2 intensity (Y-axis) as a function 
of cell circularity (X-axis). A) Response for normal volunteer population across 
approximately 20,000 cells. B) Response for FA subject across approximately 100 cells. The 
color bars depict locations of maximum clustering as red, but are scaled to different values 
based on the total number of cells.
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Figure 7. 
Tissue autofluorescence (A) and clinical (B) images of the leukoplakia in the FA patient. 
This leukoplakia was considered as a high-risk lesion based on the clinical appearance and 
due to the loss of fluorescence when examined with the VELscope (A).
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Figure 8. 
Low (A) and high (B) power microscopic images of the excisional biopsy of the leukoplakia 
revealed epithelial hyperplasia with moderate dysplasia. The scale bar represents 100 μM.
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Table 1
Results from ANOVA test for brush biopsy samples
Parameter Subject Group Median Value p-value
Cytometric Biomarkers
N-C Ratio FA 0.12 p = 0.613
Normal 0.11
Nuclear Area (px) FA 393.00 p< 0.001
Normal 247.70
Cell Circularity FA 0.59 p< 0.001
Normal 0.40
Cell Area (px2) FA 2916.00 p = 0.219
Normal 2312.00
Molecular Biomarkers
Nuclear MCM2 (Mean) (afu) FA 86.32 p< 0.001
Normal 28.61
Nuclear StDev MCM2 (afu) FA 7.15 p = 0.014
Normal 4.12
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